NCT05373914View on ClinicalTrials.gov

RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2UnknownINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

March 31, 2024

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Cudetaxestat (BLD-0409)

Cudetaxestat - 250mg tablets (orally)

DRUG

Control: Matching Placebo

Placebo - 250mg tablets (orally)

Sponsors

Lead Sponsor

Blade Therapeutics

All Listed Sponsors

lead

Blade Therapeutics

INDUSTRY

NCT05373914 - RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter